Introduction: Cannabis: From Pariah to prescription

Journal of Cannabis Therapeutics

Volumn 3, Issue 3, 2003, Pages 1-29

  Russo, Ethan ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

Alternative delivery systems; Cannabidiol; Cannabis; Herbal treatment; Medical marijuana; Psychopharmacology; THC

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTINOCICEPTIVE AGENT; ANXIOLYTIC AGENT; BRONCHODILATING AGENT; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABIS DERIVATIVE; CYTOCHROME P450; DRONABINOL; IMMUNOMODULATING AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RECEPTOR SUBTYPE;

AGITATION; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIPOLAR DISORDER; BODY WEIGHT DISORDER; BRADYCARDIA; CARBON DIOXIDE EXCRETION; CATALEPSY; CHRONIC PAIN; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG LEGISLATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SYNTHESIS; GENETIC SELECTION; GREENHOUSE; HUMAN; HYPERTENSION; HYPOTENSION; LIVER METABOLISM; MEDICAL DOCUMENTATION; MEDICINAL PLANT; MIGRAINE; MOLECULAR CLONING; MUSCLE SPASM; PEST MANAGEMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SUPERCRITICAL FLUID EXTRACTION; TACHYCARDIA; WITHDRAWAL SYNDROME;

EID: 1242308970     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v03n03_01     Document Type: Review

References (114)

1. Abrams, D., R. Leiser, J. Hilton, S. Shade, T. Elbeik, F. Aweeka, N. Benowitz, B. Bredt, B. Kosel, J. Aberg, S. Deeks, T. Mitchell, K. Mulligan, J. McCune, and M. Schambelan. 2002. Short-term effects of cannabinoids in patients with HIV-1 infection. Paper read at Symposium on the Cannabinoids, July 13, at Asilomar Conference Center, Pacific Grove, CA.
2. Abuse, United States Commission on Marihuana and Drug. 1972. Marihuana: A signal of misunderstanding; First report. Washington: U.S. Govt. Print. Off.
3. Adams, M. D., J. T. Earnhardt, B. R. Martin, L. S. Harris, W. L. Dewey, and R. K. Razdan. 1977. A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia 33 (9):1204-5.
4. Aldrich, M. R. 1997. History of therapeutic cannabis. In Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana, edited by M. L. Mathre. NC: McFarland.
5. Anonymous. 2003. Guidelines for cultivating cannabis for medicinal purposes [Voorschriften voor de verbouw van cannabis voor medicinale doeleinden]. J Cannabis Therapeutics 3 (2):51-61.
6. Baker, D., G. Pryce, J. L. Croxford, P. Brown, R. G. Pertwee, J. W. Huffman, and L. Layward. 2000. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (6773):84-7.
7. Baker, D., G. Pryce, G. Giovannoni, and A. J. Thompson. 2003. The therapeutic potential of cannabis. Lancet Neurology 2 (May):291-298.
8. Ben-Shabat, S., E. Fride, T. Sheskin, T. Tamiri, M. H. Rhee, Z. Vogel, T. Bisogno, L. De Petrocellis, V. Di Marzo, and R. Mechoulam. 1998. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353 (1):23-31.
9. Bisogno, T., L. Hanus, L. De Petrocellis, S. Tchilibon, D. E. Ponde, I. Brandi, A. S. Moriello, J. B. Davis, R. Mechoulam, and V. Di Marzo. 2001. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134 (4):845-52.
10. Broom, S. L., K. J. Sufka, M. A. Elsohly, and R. A. Ross. 2001. Analgesic and reinforcing proerties of delta9-THC-hemisuccinate in adjuvant-arthritic rats. J Cannabis Therapeutics 1 (3-4):171-182.
11. Browne, R. G., and A. Weissman. 1981. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21 (8-9 Suppl): 227S-234S.
12. Burstein, S. 1992. Eicosanoids as mediators of cannabinoid action. In Marijuana/Cannabinoids: Neurobiology and neurophysiology of drug abuse, edited by L. Murphy and A. Bartke. Boca Raton: CRC Press.
13. Cabral, G. 2001. Immune system. In Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential, edited by F. Grotenhermen and E. B. Russo. Binghamton, NY: Haworth Press.
14. Campbell, F. A., M. R. Tramber, D. Carroll, D. J. M. Reynolds, R. A. Moore, and H. J. McQuay. 2001. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. Brit Medl J 323 (7 July):1-6.
15. Carlini, E. A., and J. M. Cunha. 1981. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21 (8-9 Suppl):417S-427S.
16. Casanova, M. L., C. Blazquez, J. Martinez-Palacio, C. Villanueva, M. J. Fernandez-Acenero, J. W. Huffman, J. L. Jorcano, and M. Guzman. 2003. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 (1):43-50.
17. Challapalli, P. V., and A. L. Stinchcomb. 2002. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm 241 (2):329-39.
18. Chang, A. E., D. J. Shiling, R. C. Stillman, N. H. Goldberg, C. A. Seipp, I. Barofsky, R. M. Simon, and S. A. Rosenberg. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91 (6):819-24.
19. Cichewicz, D. L., Z. L. Martin, F. L. Smith, and S. P. Welch. 1999. Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: Dose-response analysis and receptor identification. J Pharmacol Exp Ther 289 (2):859-67.
20. Cichewicz, D. L., and S. P. Welch. 2002. The effects of oral administration of delta-9-THC on morphine tolerance and physical dependence. Paper read at Symposium on the Cannabinoids, July 13, at Asilomar Conference Center, Pacific Grove, CA.
21. Consroe, P. 1998. Brain cannabinoid systems as targets for the therapy of neurological disorders [In Process Citation]. Neurobiol Dis 5 (6 Pt B):534-51.
22. Corral, V.L. 2001. Differential effects of medical marijuana based on strain and route of administration: A three-year observational study. J Cannabis Therapeutics 1 (3-4):43-59.
23. da Orta, Garcia. 1913. Colloquies on the simples and drugs of India. London: Henry Sotheran.
24. de Meijer, E. 2003. The breeding of cannabis cultivars for pharmaceutical end uses. In Medicinal uses of cannabis and cannabinoids, edited by B. A. Whittle, G. W. Guy and P. Robson. London: Pharmaceutical Press.
25. de Meijer, E. P., M. Bagatta, A. Carboni, P. Crucitti, V. M. Moliterni, P. Ranalli, and G. Mandolino. 2003. The inheritance of chemical phenotype in Cannabis sativa L. Genetics 163 (1):335-46.
26. De Petrocellis, L., D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo. 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95 (14):8375-80.
27. Dixon, W. E. 1899. The pharmacology of Cannabis indica. Brit Med J 2:1354-1357.
28. Dixon, W. E. 1921. A manual of pharmacology. 5th ed. London: Edward Arnold & Co.
29. Elsohly, M. A., T. L. Little, Jr., A. Hikal, E. Harland, D. F. Stanford, and L. Walker. 1991. Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav 40 (3):497-502.
30. Falk, A. A., M. T. Hagberg, A. E. Lof, E. M. Wigaeus-Hjelm, and Z. P. Wang. 1990. Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation. Scand J Work Environ Health 16 (5):372-8.
31. Farlow, J. W. 1889. On the use of belladonna and Cannabis indica by the rectum in gynecological practice. Boston Med Surg Jl 120:507-509.
32. Fride, E. 2002. Cannabinoids and cystic fibrosis: A novel approach. J Cannabis Therapeutics 2 (1):59-71.
33. Fride, E. 2002. Cannabinoids and feeding: The role of the endogenous cannabinoid system as a trigger for newborn suckling. J Cannabis Therapeutics 2 (3-4):51-62.
34. Gieringer, D. 1996. Why marijuana smoke harm reduction? Bull Multidisciplinary Assoc Psychedelic Stud 6 (64-66).
35. Gieringer, D. 1996. Waterpipe study. Bull Multidisciplinary Assoc Psychedelic Stud 6:59-63.
36. Gieringer, D. 2001. Medical use of cannabis: Experience in California. In Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential, edited by F. Grotenhermen and E. Russo, Binghamtom, NY; Haworth Press.
37. Gieringer, D. H. 2001. Cannabis "vaporization": A promising strategy for smoke harm reduction. J Cannabis Therapeutics 1 (3-4):153-170.
38. Grinspoon, L., and J. B. Bakalar. 1998. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 30 (2):171-7.
39. Grinspoon, L., and J. B. Bakalar. 1997. Marihuana, the forbidden medicine. Rev. and exp. ed. New Haven: Yale University Press.
40. Guy, G. W., B. A. Whittle, F. A. Javid, C. Wright, and R. J. Naylor. 2002. An inhibitory role for cannabinoids in the control of motion sickness in Suncus marinus. Paper read at Symposium on the Cannabinoids, at Asilomar Conference Center, Pacific Grove, CA.
41. Guyatt, G. H., J. L. Keller, R. Jaeschke, D. Rosenbloom, J. D. Adachi, and M. T. Newhouse. 1990. The n-of-1 randomized controlled trial: Clinical usefulness. Our three-year experience. Ann Intern Med 112 (4):293-9.
42. Haines, T., C. D. Adler, T. P. Farley, E. B. Russo, L. Grinspoon, and R. W. Sweet. 2000. Living with our drug policy. Fordham Urban Law Jl 28 (1):92-129.
43. Hampson, A. J., M. Grimaldi, J. Axelrod, and D. Wink. 1998. Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95 (14):8268-73.
44. Herodotus. 1998. The histories. Translated by R. Waterfield and C. Dewald. Oxford [England]; New York: Oxford University Press.
45. Holdcroft, A., M. Smith, A. Jacklin, H. Hodgson, B. Smith, M. Newton, and F. Evans. 1997. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52 (5):483-6.
46. Jarvinen, T., D. Pate, and K. Laine. 2002. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 95 (2):203.
47. Joy, Janet E., Stanley J. Watson, and John A. Benson, Jr. 1999. Marijuana and medicine: Assessing the science base. Washington, DC: Institute of Medicine.
48. Karniol, I. G., I. Shirakawa, R. N. Takahashi, E. Knobel, and R. E. Musty. 1975. Effects of delta9-tetrahydrocannabinol and cannabinol in man. Pharmacol 13 (6):502-12.
49. Killestein, J., E. L. Hoogervorst, M. Reif, N. F. Kalkers, A. C. Van Loenen, P. G. Staats, R. W. Gorter, B. M. Uitdehaag, and C. H. Polman. 2002. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurol 58 (9):1404-7.
50. Lorenzetti, B. B., G. E. Souza, S. J. Sarti, D. Santos Filho, and S. H. Ferreira. 1991. Myrcene mimics the peripheral analgesic activity of lemongrass tea. J Ethnopharmacol 34 (1):43-8.
51. Malfait, A. M., R. Gallily, P. F. Sumariwalla, A. S. Malik, E. Andreakos, R. Mechoulam, and M. Feldmann. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97 (17):9561-6.
52. Mannische, L. 1989. An ancient Egyptian herbal. Austin: University of Texas.
53. McKallip, R. J., C. Lombard, M. Fisher, B. R. Martin, S. Ryu, S. Grant, P. S. Nagarkatti, and M. Nagarkatti. 2002. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2):627-34.
54. McPartland, J. M., R. C. Clarke, and D. P. Watson. 2000. Hemp diseases and pests: Management and biological control. Wallingford, UK: CABI.
55. McPartland, J. M., and E. B. Russo. 2001. Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Therapeutics 1 (3-4):103-132.
56. Mechoulam, R., and S. Ben-Shabat. 1999. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep 16 (2): 131-43.
57. Mechoulam, R., L. A. Parker, and R. Gallily. 2002. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42 (11 Suppl): 11S-19S.
58. Medicines Control, Agency. 1997. Rules and guidance for pharmaceutical manufacturers 1997: Orange Guide. London: Stationery Office Agency.
59. Merritt, J. C., W. J. Crawford, P. C. Alexander, A. L. Anduze, and S. S. Gelbart. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmol 87 (3):222-8.
60. Mittleman, M. A., R. A. Lewis, M. Maclure, J. B. Sherwood, and J. E. Muller. 2001. Triggering myocardial infarction by marijuana. Circulation 103 (23):2805-9.
61. Müller-Vahl, K. R., U. Schneider, H. Kolbe, and H. M. Emrich. 1999. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156 (3):495.
62. Muller-Vahl, K. R., U. Schneider, H. Prevedel, K. Theloe, H. Kolbe, T. Daldrup, and H. M. Emrich. 2003. Delta9-tetrahydrocannabinol (THC) is effective in the treatment of Tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry 64 (4):459-465.
63. Musty, R. E., and R. Rossi. 2001. Effects of smoked cannabis and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Therapeutics 1 (1):29-42.
64. O'Shaughnessy, W. B. 1838-1840. On the preparations of the Indian hemp, or gunjah (Cannabis indica); Their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of the Medical and Physical Society of Bengal:71-102, 421-461.
65. Pate, D. 1994. Chemical ecology of cannabis. J Interntl Hemp Assoc 2:32-37.
66. Pertwee, R. G. 2001. Cannabinoid receptors and pain. Prog Neurobiol 63 (5):569-611.
67. Pertwee, R. G. 2001. Cannabinoids and the gastrointestinal tract. Gut 48 (6):859-67.
68. Pertwee, R.G. 1998. Advanced in cannabinoid receptor pharmacology in cannabis. In Cannabis: The genus Cannabis, edited by D. T. Brown. Amsterdam: Harwood Academic Publishers.
69. Petro, D. J. 1980. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 21 (1):81, 85.
70. Petro, D. J. 2002. Cannabis in multiple sclerosis: Women's health concerns. J Cannabis Therapeutics 2 (3-4):161-175.
71. Potter, D. 2003. Growth and morphology of medicinal cannabis. In Medicinal uses of cannabis and cannabinoids, edited by B. A. Whittle, G. W. Guy and P. Robson. London: Pharmaceutical Press.
72. Randall, R. C., and A. M. O'Leary. 1998. Marijuana Rx: The patients' fight for medicinal pot. New York: Thunder's Mouth Press.
73. Rao, V. S., A. M. Menezes, and G. S. Viana. 1990. Effect of myrcene on nociception in mice. J Pharm Pharmacol 42 (12):877-8.
74. Regelson, W., J. R. Butler, J. Schulz, T. Kirk, L. Peek, M. L. Green, and M. O. Zalis. 1976. Delta 9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In Braude M. C., Szara S., ed. Pharmacology of marihuana. Vol 2. New York, Raven Press.
75. Reynolds, J. R. 1890. Therapeutical uses and toxic effects of Cannabis indica. Lancet 1:637-638.
76. Robson, P., and G. W. Guy. 2003. Clinical studies of cannabis-based medicine. In Medicinal uses of cannabis and cannabinoids, edited by B. A. Whittle, G. W. Guy and P. Robson. London: Pharmaceutical Press.
77. Roth, M. D., J. A. Marques-Magallanes, M. Yuan, W. Sun, D. P. Tashkin, and O. Hankinson. 2001. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24 (3):339-44.
78. Russo, E. 1998. Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain 76 (1-2):3-8.
79. Russo, E. 2001. Cannabinoids in pain management. Study was bound to conclude that cannabinoids had limited efficacy. Brit Med J 323 (7323):1249-50.
80. Russo, E. 2002. Cannabis treatments in obstetrics and gynecology: A historical review. J Cannabis Therapeutics 2 (3-4):5-35.
81. Russo, E. B., and J. M. McPartland. 2003. Cannabis is more than simply delta (9)-tetrahydrocannabinol. Psychopharmacol (Berl) 165 (4):431-2.
82. Russo, E. B. 2001. Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions. Binghamton, NY: Haworth Press.
83. Russo, E. B. 2002. Role of cannabis and cannabinoids in pain management. In Pain management: A practical guide for clinicians, edited by R. S. Weiner. Boca Raton, FL: CRC Press.
84. Russo, E. B. 2003. The history of cannabis as medicine. In Medicinal uses of cannabis and cannabinoids, edited by B. A. Whittle, G. W. Guy and P. Robson. London: Pharmaceutical Press.
85. Russo, E. B., M. L. Mathre, A. Byrne, R. Velin, P. J. Bach, J. Sanchez-Ramos, and K. A. Kirlin. 2002. Chronic cannabis use in the Compassionate Investigational New Drug Program: An examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Therapeutics 2 (1):3-57.
86. Russo, E. B., A. Merzouki, J. Molero Mesa, and K. A. Frey. 2003. Cannabis improves night vision: A pilot study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif Mountains of Northern Morocco. Journal of Ethnopharmacology (Submitted).
87. Russo, E.B., and M. Stortz. 2003. An interview with Markus Storz: June 19, 2002. J Cannabis Therapeutics 3 (1):67-78.
88. Russo, E. B. 2001. Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Therapeutics 1 (2):21-92.
89. Sanchez, C., I. Galve-Roperh, C. Canova, P. Brachet, and M. Guzman. 1998. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436 (1):6-10.
90. Showalter, V. M., D. R. Compton, B. R. Martin, and M. E. Abood. 1996. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278 (3):989-99.
91. Sidney, S., J. E. Beck, I. S. Tekawa, C. P. Quesenberry, and G. D. Friedman. 1997. Marijuana use and mortality. Am J Public Health 87 (4):585-90.
92. Straub, W. 1931. Intoxicating drugs. In Lane Lectures on Pharmacology, edited by W. Straub. Stanford, CA: Stanford University Press.
93. Tashkin, D. P., S. Reiss, B. J. Shapiro, B. Calvarese, J. L. Olsen, and J. W. Lodge. 1977. Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev Respir Dis 115 (1):57-65.
94. Tashkin, D. P., M. S. Simmons, D. L. Sherrill, and A. H. Coulson. 1997. Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. Am J Respir Crit Care Med 155 (1):141-8.
95. Tashkin, D. P., G. C. Baldwin, T. Sarafian, S. Dubinett, and M. D. Roth. 2002. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42 (11 Suppl):71S-81S.
96. Tashkin, D. P. 2001. Respiratory risks from marijuana smoking. In Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential, edited by F. Grotenhermen and E. Russo. Binghamton, NY: Haworth Press.
97. Tyler, V. E. 1994. Herbs of choice: the therapeutic use of phytomedicinals. New York: Pharmaceutical Products Press.
98. Vaccani, A., P. Massi, and D. Parolaro. 2003. Inhibition of human glioma cell growth by the non psychoactive cannabidiol. Paper read at First European Workshop on Cannabinoid Research., April 4-5, at Madrid.
99. Vaney, C., P. Jobin, F. Tschopp, M. Heinzel, and M. Schnelle. 2002. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis. Paper read at Symposium on the Cannabinoids, July 13, at Asilomar Conference Center, Pacific Grove, CA.
100. Viola, H., C. Wasowski, M. Levi de Stein, C. Wolfman, R. Silveira, F. Dajas, J. H. Medina, and A. C. Paladini. 1995. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 61 (3):213-6.
101. Volicer, L., M. Stelly, J. Morris, J. McLaughlin, and B. J. Volicer. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12 (9):913-9.
102. Wachtel, S.R., M. A. ElSohly, R. A. Ross, J. Ambre, and H. de Wit. 2002. Comparison of the subjective effects of delta9-tetrahydrocannabinol and marijuana in humans. Psychopharmacol 161:331-339.
103. Wallace, M. J., B. R. Martin, and R. J. DeLorenzo. 2002. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452 (3):295-301.
104. Ware, M. A., and V. L. Tawfik. 2001. A review of the respiratory effects of smoked cannabis: Implications for clinical trials. Paper read at Symposium on the Cannabinoids, June 30, at El Escorial, Spain.
105. Weil, A. T., N. E. Zinberg, and J. M. Nelsen. 1968. Clinical and psychological effects of marihuana in man. Science 162 (859):1234-42.
106. West, M.E. 1991. Cannabis and night vision. Nature 351:703-704.
107. Whittle, B. A., and G. W. Guy. 2003. Development of cannabis-based medicines; risk, benefit and serendipity. In Medicinal uses of cannabis and cannabinoids, edited by B. A. Whittle, G. W. Guy and P. Robson. London: Pharmaceutical Press.
108. Whittle, B. A., G. W. Guy, and P. Robson. 2001. Prospects for new cannabis-based prescription medicines. J Cannabis Therapeutics 1 (3-4):183-205.
109. Williams, S. J., J. P. Hartley, and J. D. Graham. 1976. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 31 (6):720-3.
110. Williamson, E. M., and F. J. Evans. 2000. Cannabinoids in clinical practice. Drugs 60 (6):1303-14.
111. Wilson, D. M., J. Peart, B. R. Martin, D. T. Bridgen, P. R. Byron, and A. H. Lichtman. 2002. Physiochemical and pharmacological characterization of a delta (9)-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend 67 (3):259-67.
112. Wright, T. L. 1862. Correspondence. Cincinnati Lancet and Observer 5 (4):246-247.
113. Zuardi, A. W., I. Shirakawa, E. Finkelfarb, and I. G. Karniol. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacol 76 (3):245-50.
114. Zuardi, A. W., and F. S. Guimaraes. 1997. Cannabidiol as an anxiolytic and anti-psychotic. In Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana, edited by M. L. Mathre. Jefferson, NC: McFarland.